Immunology
A new immunoassay monitors HCV-infected patients for treatment response
Published in Hepatitis Weekly, April 19th, 2004
According to recent research from Egypt, "hepatitis C virus (HCV) infection continues to be an emerging global health concern. With the advent of additional treatment protocols, a simple and reliable assay for changes in HCV load may permit more frequent patient assessment and tailoring of the therapeutic regimen. Recently, we have developed a highly sensitive and specific enzyme immunoassay (EIA) for the detection of an HCV-nonstructural 4 (NS4) antigen in serum."
"Here, we evaluated the efficacy of the developed assay in monitoring the virologic responses to pegylated...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-04-19)
More Articles from Hepatitis Weekly
- Hepatitis C Therapy
Forty-eight weeks of therapy may not be long enough for treating HCV type 1 - Adverse Drug Effects
Flutamide produces liver toxicity and a death in Germany - Diagnostics
Highly specific probes detect hepatitis C virus in liver tissues - Liver Cancer
Methylated p16 may be a tumor marker for hepatocellular carcinoma - Oncology
Human leukocyte antigen alleles link hepatitis C virus to liver cancer - Angiology
Contrast agent concentration in mouse blood used to determine tumor vascularity - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
